Condition (MeSH)
Thymoma
ClinicalTrials.gov lists 126 trials for Thymoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 14.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
126 of the 126 trials are tagged with Thymoma itself; the rest are tagged with a narrower condition beneath it.
When did Thymoma trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 12
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 8 |
| 2025 | 6 |
| 2024 | 8 |
| 2023 | 9 |
| 2022 | 8 |
| 2021 | 4 |
| 2020 | 8 |
| 2019 | 2 |
| 2018 | 12 |
| 2017 | 7 |
Showing 10 of 26 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 9 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 22 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 72 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Thymoma trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 17 |
| Phase 1/2 | 4 |
| Phase 2 | 55 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |
| Phase 4 | 2 |
| Not applicable | 22 |
| Observational | 20 |
How many Thymoma trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 7 |
| Recruiting | 21 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 10 |
| Completed | 51 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Thymoma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 14 |
| Novartis Pharmaceuticals | 3 |
| Eastern Cooperative Oncology Group | 2 |
| Intuitive Surgical | 2 |
| National Cancer Center, Japan | 2 |
Which drugs are being tested for Thymoma? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PEMBROLIZUMAB | 6 |
| Cytoxan | 4 |
| (nab)-paclitaxel | 3 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Sunitinib 4/2 | 5 |
| Radiotherapy | 4 |
| or carboplatin | 3 |
| AG chemotherapy | 2 |
| Cisplatin 1 | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Thymoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death NOS | 93 | 4 |
| Myasthenia gravis | 29 | 2 |
| Dyspnea | 21 | 7 |
| Lung infection | 17 | 6 |
| Hypoxia | 16 | 8 |
Showing 5 of 10 adverse events.
Which publications cover Thymoma? (106)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. | Med (New York, N.Y.) | 2025 | Yes |
| Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2025 | Yes |
| Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. | The Lancet. Oncology | 2025 | Yes |
| Subxiphoid versus lateral intercostal thoracoscopic thymectomy for suspected thymoma: Results of a randomized controlled trial. | The Journal of thoracic and cardiovascular surgery | 2024 | Yes |
| High levels of expression of Trop-2 in thymic epithelial tumors. | Lung cancer (Amsterdam, Netherlands) | 2023 | Yes |
Showing 5 of 106 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Thymoma | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Thymoma | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Thymoma | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Thymoma | Lifetime prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| Thymoma | Lifetime prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Thymoma | 99867 | Exact | Orphadata Science knowledge files, Product 1 |
| Thymoma | 99867 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.